CARDIFF ONCOLOGY INC (CRDF) Stock Analyst Ratings
NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to CRDF. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.22. This target is 220.57% above the current price.
CRDF was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CRDF.
In the previous month the buy percentage consensus was at a similar level.
CRDF was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-06 | Craig-Hallum | Initiate | Buy |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2023-03-29 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-07 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-16 | HC Wainwright & Co. | Maintains | Buy |
| 2022-09-13 | Piper Sandler | Maintains | Overweight |
| 2022-08-29 | Baird | Maintains | Outperform |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-02-28 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-08 | Baird | Initiate | Outperform |
| 2021-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-10 | HC Wainwright & Co. | Maintains | Buy |